328 related articles for article (PubMed ID: 33520361)
21. An In Vitro Comparison of Costimulatory Domains in Chimeric Antigen Receptor T Cell for Breast Cancer Treatment.
Khuisangeam N; Jewmoung S; Thaiwong R; Tudsamran S; Hirankarn N; Suppipat K; Tawinwung S
J Immunol Res; 2022; 2022():2449373. PubMed ID: 36457849
[TBL] [Abstract][Full Text] [Related]
22. Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer.
Zysk A; DeNichilo MO; Panagopoulos V; Zinonos I; Liapis V; Hay S; Ingman W; Ponomarev V; Atkins G; Findlay D; Zannettino A; Evdokiou A
Cancer Lett; 2017 Feb; 386():141-150. PubMed ID: 27865798
[TBL] [Abstract][Full Text] [Related]
23. A VHH-Based Anti-MUC1 Chimeric Antigen Receptor for Specific Retargeting of Human Primary T Cells to MUC1-Positive Cancer Cells.
Rajabzadeh A; Rahbarizadeh F; Ahmadvand D; Kabir Salmani M; Hamidieh AA
Cell J; 2021 Jan; 22(4):502-513. PubMed ID: 32347044
[TBL] [Abstract][Full Text] [Related]
24. IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors
Koneru M; Purdon TJ; Spriggs D; Koneru S; Brentjens RJ
Oncoimmunology; 2015 Mar; 4(3):e994446. PubMed ID: 25949921
[TBL] [Abstract][Full Text] [Related]
25. IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human V gamma 9V delta 2 T cells for adoptive immunotherapy.
Thedrez A; Harly C; Morice A; Salot S; Bonneville M; Scotet E
J Immunol; 2009 Mar; 182(6):3423-31. PubMed ID: 19265120
[TBL] [Abstract][Full Text] [Related]
26. The capacity of CD4
Holmen Olofsson G; Pedersen SR; Aehnlich P; Svane IM; Idorn M; Thor Straten P
Cytotherapy; 2021 Jul; 23(7):582-589. PubMed ID: 33785258
[TBL] [Abstract][Full Text] [Related]
27. Effective Targeting of TAG72
Murad JP; Kozlowska AK; Lee HJ; Ramamurthy M; Chang WC; Yazaki P; Colcher D; Shively J; Cristea M; Forman SJ; Priceman SJ
Front Immunol; 2018; 9():2268. PubMed ID: 30510550
[TBL] [Abstract][Full Text] [Related]
28. Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2.
Gargett T; Brown MP
Cytotherapy; 2015 Apr; 17(4):487-95. PubMed ID: 25573334
[TBL] [Abstract][Full Text] [Related]
29. MUC1 as a target for CAR-T therapy in head and neck squamous cell carinoma.
Mei Z; Zhang K; Lam AK; Huang J; Qiu F; Qiao B; Zhang Y
Cancer Med; 2020 Jan; 9(2):640-652. PubMed ID: 31800160
[TBL] [Abstract][Full Text] [Related]
30. Significantly increased anti-tumor activity of carcinoembryonic antigen-specific chimeric antigen receptor T cells in combination with recombinant human IL-12.
Chi X; Yang P; Zhang E; Gu J; Xu H; Li M; Gao X; Li X; Zhang Y; Xu H; Hu J
Cancer Med; 2019 Aug; 8(10):4753-4765. PubMed ID: 31237116
[TBL] [Abstract][Full Text] [Related]
31. CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth.
Zhou R; Yazdanifar M; Roy LD; Whilding LM; Gavrill A; Maher J; Mukherjee P
Front Immunol; 2019; 10():1149. PubMed ID: 31178870
[TBL] [Abstract][Full Text] [Related]
32. Universal Ready-to-Use Immunotherapeutic Approach for the Treatment of Cancer: Expanded and Activated Polyclonal γδ Memory T Cells.
Polito VA; Cristantielli R; Weber G; Del Bufalo F; Belardinilli T; Arnone CM; Petretto A; Antonucci L; Giorda E; Tumino N; Pitisci A; De Angelis B; Quintarelli C; Locatelli F; Caruana I
Front Immunol; 2019; 10():2717. PubMed ID: 31824502
[TBL] [Abstract][Full Text] [Related]
33. Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer.
Sanchez C; Chan R; Bajgain P; Rambally S; Palapattu G; Mims M; Rooney CM; Leen AM; Brenner MK; Vera JF
Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):123-31, S1. PubMed ID: 23295316
[TBL] [Abstract][Full Text] [Related]
34. CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation.
Bajgain P; Tawinwung S; D'Elia L; Sukumaran S; Watanabe N; Hoyos V; Lulla P; Brenner MK; Leen AM; Vera JF
J Immunother Cancer; 2018 May; 6(1):34. PubMed ID: 29747685
[TBL] [Abstract][Full Text] [Related]
35. Clinical applications of gamma delta T cells with multivalent immunity.
Deniger DC; Moyes JS; Cooper LJ
Front Immunol; 2014; 5():636. PubMed ID: 25566249
[TBL] [Abstract][Full Text] [Related]
36. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
[TBL] [Abstract][Full Text] [Related]
37. Cytokine-mediated activation of human ex vivo-expanded Vγ9Vδ2 T cells.
Domae E; Hirai Y; Ikeo T; Goda S; Shimizu Y
Oncotarget; 2017 Jul; 8(28):45928-45942. PubMed ID: 28521284
[TBL] [Abstract][Full Text] [Related]
38. Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells.
Gao Z; Tong C; Wang Y; Chen D; Wu Z; Han W
J Genet Genomics; 2019 Aug; 46(8):367-377. PubMed ID: 31466926
[TBL] [Abstract][Full Text] [Related]
39. Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer.
Mohammed S; Sukumaran S; Bajgain P; Watanabe N; Heslop HE; Rooney CM; Brenner MK; Fisher WE; Leen AM; Vera JF
Mol Ther; 2017 Jan; 25(1):249-258. PubMed ID: 28129119
[TBL] [Abstract][Full Text] [Related]
40. Interleukin-18 activates Vγ9Vδ2
Murday AS; Chaudhry S; Pauza CD
Immunology; 2017 Aug; 151(4):385-394. PubMed ID: 28342224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]